SBIR/STTR Research Award

THE OBJECTIVE OF THIS PROPOSAL IS TO DEVELOP SENSITIVE, NONISOTOPIC BIOLUMINESCENT LIGAND RECEPTOR ASSAYS FOR OXYTOCIN (OT) AND ARGININE-VASOPRESSIN (AVP).

Award identifier d27267ef136a7026a38bb367046002d9ac83e57f23231e4b9a29f1f0e486646fAwarding agency Department of Health and Human Services

Award amount

$49,205

Program and phase

SBIR · Phase I

Award year

1985

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
Not reported
Recipient company
Lucitech Inc.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

THE OBJECTIVE OF THIS PROPOSAL IS TO DEVELOP SENSITIVE, NONISOTOPIC BIOLUMINESCENT LIGAND RECEPTOR ASSAYS FOR OXYTOCIN (OT) AND ARGININE-VASOPRESSIN (AVP). OUR LABORATORY HAS DEVELOPED METHODS TO COVALENTLY BIND FIREFLY LUCIFERIN TO VARIOUS BIOLOGICALLY ACTIVE MOLECULES. UNDER THE APPROPRIATE CONDITIONS, THE LUCIFERIN-DERIVED MOLECULE RETAINS ITS BIOLOGIC FUNCTION AND ALSO HAS LUCIFERIN ACTIVITY (I.E., THE ABILITY TO PRODUCE PHOTONS OF LIGHT IN THE PRESENCE OF LUCIFERASE, MAGNESIUM, AND ATP). IN EFFECT, WE ARE ABLE TO ""LABEL'' VARIOUS MOLECULES, SUCH AS PROTEINS, PEPTIDES, AND STEROIDS WITH A NONRADIOACTIVE PROBE. THE LUCIFERIN-DERIVED MOLECULE MAY THEN BE USED IN BIOLUMINESCENT LIGAND RECEPTOR ASSAYS, ANALOGOUS TO RADIOLIGAND RECEPTOR ASSAYS. BECAUSE OF THE SENSITIVITY OF THE LUCIFERIN-LUCIFERASE REACTION (MEASUREABLE LIGHT IS PRODUCED WITH 10 ATAMOLES OF LUCIFERIN) THESE ASSAYS ARE 5005000-FOLD MORE SENSITIVE THAN EXISTING ASSAYS USING 3H-LABELED COMPOUNDS. THIS INCREASED SENSITIVITY IS EXTREMELY IMPORTANT FOR THE LOCALIZATION AND CHARACTERIZATION OF SPECIFIC NEUROPEPTIDE RECEPTOR SITES IN DISCRETE BRAIN REGIONS. OT AND AVP NEURONS HAVE BEEN VISUALIZED IN MANY BRAIN REGIONS; HOWEVER, SPECIFIC BINDING SITES HAVE BEEN DIFFICULT TO LOCALIZE AND CHARACTERIZE DUE TO THE RELATIVELY LOW SPECIFIC ACTIVITY OF THE AVAILABLE RADIOLABELED LIGANDS. CONSEQUENTLY, THE INCREASED SENSITIVITY OF LUCIFERIN-DERIVED OT AND AVP WILL BE EXTREMELY IMPORTANT FOR THE LOCALIZATION AND CHARACTERIZATION OF SPECIFIC RECEPTOR SITES IN DISCRETE BRAIN REGIONS. THIS INFORMATION WILL BE VERY IMPORTANT IN FURTHER ELUCIDATION OF THE PHYSIOLOGICAL IMPORTANCE OF OT AND AVP IN BRAIN FUNCTION. THE SECOND GOAL OF THIS RESEARCH WILL BE TO DEVELOP LUCIFERIN ANALOGS WHICH MAY BE MORE READILY BOUND TO OTHER MOLECULES, ENABLING US TO MORE WIDELY UTILIZE LUCIFERIN-DERIVED COMPOUNDS AS AN ALTERNATIVE TO RADIOLABELED COMPOUNDS.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.